Itraconazole is a first-generation triazole agent with an extended spectrum of activity; it is licensed in adults for superficial and systemic fungal infections; no recommendation has been yet established for use in children patients. Its variable and unpredictable oral bioavailability make it difficult to determine the optimal dosing regimen.
Summary
Itraconazole is a first-generation triazole agent with an extended spectrum of activity; it is licensed in adults for superficial and systemic fungal infections; no recommendation has been yet established for use in children patients. Its variable and unpredictable oral bioavailability make it difficult to determine the optimal dosing regimen.
Hence, therapeutic drug monitoring, highly available in clinical practice, may improve itraconazole treatment success and safety. The aim of the study was to describe in paediatrics the oral itraconazole pharmacokinetics, used for prophylaxis. Moreover, we evaluated the utility of its therapeutic drug monitoring in this cohort. A fully validated chromatographic method was used to quantify itraconazole concentration in plasma collected from paediatric patients, at the end of dosing interval. Associations between variables were tested using the Pearson test. Mann-Whitney U test has been used to probe the influence of categorical variables on continuous ones. Any predictive power of the considered variables was finally evaluated through univariate and multivariate linear and logistic regression analyses. A high inter-individual variability was shown; ethnicity (beta coefficient, β −0.161 and interval of confidence at 95%, IC −395.035; −62.383) and gender (β 0.123 and IC 9.590; 349.395) remained in the final linear regression model with P value of .007 and .038, respectively. This study highlights that therapeutic drug monitoring is required to achieve an adequate target itraconazole serum exposure.
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| INTRODUCTION
Invasive fungal infections (IFIs) are a significant cause of morbidity and mortality in children. Successful management of these systemic infections requires identification of the causative pathogen, appropriate antifungal selection, and optimisation of its pharmacokinetic and pharmacodynamic properties, to maximise its antifungal activity and minimise toxicity and the emergence of resistance.
1 Azoles remain the first choice for prevention and treatment of IFIs; 2 however, the clinical use of these drugs is characterized by frequent pharmacological disadvantage in terms of pharmacokinetic variability and drug-drug interactions.
3
Itraconazole (ITC, Sporanox) is a first-generation azole approved by the United States Food and Drug Administration (FDA) for the treatment of fungal infections; it is well tolerated and effective for superficial and systemic fungal infections; no recommendation has been yet established for use in children patients. 4 ITC is lipophilic and it interferes with the synthesis of the cytochrome P450 (CYP)-dependent enzyme lanosterold 14-α-emethylase, an ergosterol precursor essential for the fungal cell membranes. 5, 6 ITC levels are 2-20 times higher in tissues, such as lungs, kidney, bone and muscles, skin, nails, and the female genital tract, than in the serum; nevertheless penetration into the cerebrospinal fluid is limited. 7 It is metabolized in liver, yielding over 30 different metabolites. In paediatric patients, ITC absorption rate from oral (OS) administration was found to be greater than capsules and higher drug plasma exposure has been observed in older children (5-12 years old).
8-12
Drug levels and treatment outcome depend on host factors, target organisms and associated interventions and therapeutic drug monitoring (TDM) can timely and appropriately guide drug dosage modifications. 13 Already published clinical TDM studies have been conducted and they observed that ITC dose modification could result in more appropriate drug levels.
14 The aim of our study was to describe, in paediatrics, the ITC OS pharmacokinetics, used for IFIs prophylaxis (OS administration), and to evaluate the utility of ITC TDM in this population.
| RESULTS
Mean, standard deviation (SD), median and median and interquartile range (IQR), 25th-75th percentiles, values for age, body mass index (BMI) and ITC plasma concentrations were resumed and compared in Table 1 ; there were no statistically significant differences in terms of baseline characteristics. The drug dosage has been evaluated with a score from 1 to 18, as shown in Table 2 .
Based on published ITC through levels cut-off for prophylaxis, [9] [10] [11] we observed that 128 patients (44.1%; median 78.00 ng/mL, IQR <limit of detection (LOD) −148.00 ng/mL) showed sub-optimal exposure, whereas 162 subjects (55.9%; median 735.00 ng/mL; IQR 431.50-1203.75 ng/mL) had concentrations higher than the efficacy defined level.
A high inter-individual variability was found between ITC C trough concentrations: the median value was 306.50 ng/mL and the IQR range was 91.00 and 781.25 ng/mL.
Pearson test showed that there were no statistically significant correlations among ITC C trough and drug dose, BMI or age. MannWhitney U did not result in statistically significant influence of sex or ethnicity on ITC exposure.
Univariate linear regression analysis was performed to evaluate the effect of ethnicity, gender, age, BMI and drug dose on ITC C trough .
Stepwise forward regression analysis was used to identify the minimum set of independent predictive variables of ITC exposure and estimate the contribution of each factor to pharmacokinetic variability; only ethnicity (beta coefficient, β −0.161 and interval of confidence at 95%, IC −395.035; −62.383) and gender (β 0.123 and IC 9.590; 349.395) remained in the final model with P value of .007 and .038, respectively (Table 3) .
Univariate logistic regression analysis was carry out to evaluate the effect of age, gender, BMI and drug dose on ITC efficacy cut-off value of 250 ng/mL. Stepwise forward regression analysis was used to identify the minimum set of independent predictive variables of the cut-off effectiveness and estimate the contribution of each factor to pharmacokinetic variability; no factors remained in the final model (Table 4) .
| DISCUSSION
Itraconazole pharmacokinetics are highly variable, probably due to its unpredictable oral bioavailability: 15, 16 it is non-linear (or saturable) exhibits prolonged clearance and slow accumulation. 17 The drug half-life is approximately 24 hours and the time to steady state is about 14 days.
16
ITC is a weakly basic Biopharmaceutics Classification System (BCS) 18 class II (low solubility/high permeability) drug with a pH-dependent dissolution (pKa value, 3.7); for this reason it requires an acidic gastric environment for adequate dissolution and absorption. In fact, ITC coadministration with gastric acidity inhibitors, such as antacids and proton pump inhibitors, reduce the extent of drug absorption. 19, 20 ITC is a substrate of P-glycoprotein (P-gp), a membrane efflux transporter.
21-24
Our results show that ITC exposure has a high inter-individual variability and participants age, BMI, ethnicity, sex or age did not significantly influence ITC pharmacokinetics. Instead, linear regression analysis showed that ethnicity (P = .007) and gender (P = .038), respectively are negative and positive, predictors of trough levels (Table 3) . Gender-related differences, such as body size and muscle mass, may result in pharmacokinetic differences; genetic variations among ethnic groups also can alter drug disposition. 25 Ethnicity may influence the disposition of P-gp-substrate drugs due to the differences in P-gp polymorphism between black and white subjects. Especially, P-gp polymorphisms may influence ITC: in a study on ITC, administered before fexofenadine, a P-gp substrate, the fexofenadine area under the concentration curve was significantly higher and T A B L E 1 Mean, standard deviation, median and interquartile range for age, body mass index and itraconazole plasma concentrations the drug clearance significantly lower in individuals with TT phenotype than in GC haplotype, indicating P-gp inhibition by ITC in TT subjects.
26
During the past decade much information about inter-gender differences has been published in adult population. 25, [27] [28] [29] [30] Considering the pharmacokinetic differences, an apparent high female CYP3A4 activity has been reported. 31 Conversely, the activity of other CYP isozymes (e.g. CYP2C19, CYP2D6, and CYP2E1) and the glucuronidation activity may be higher in males. 28, 29 Thus, different oral bioavailability, caused by different intestinal and hepatic metabolic enzymes activity, may be found. However, no evidence regarding children is available.
Moreover, women have a lower acid secretion in the stomach,
28
so the ITC absorption might be compromised due to its incomplete dissolution and unrestricted presystemic intestinal metabolism. In a study on 639 cases of invasive candidiasis, non-white race and female gender were more commonly associated with non-albicans species.
32
Evaluating the logistic regression analysis, performed to assess the effect of age, gender, BMI and drug dose on ITC efficacy cut-off for prophylactic use, no factors were retained in the final model (Table 4) . We chose to consider the steady state itraconazole trough concentration of 250 ng/ mL 9-11 for our analyses, because it is the one used by our clinicians to discriminate prophylaxis outcome. Nevertheless, more recent publications describe a new threshold for prophylaxis of 500 ng/mL. 14, 33, 34 To our knowledge, in the literature there are limited data describing the use of ITC in children; ITC single intravenous or OS dose of 2.5 mg/kg/d in children aged 7 months to 17 years is well tolerated, but it results in a high variability in drug exposure. 35 Moreover, OS dose of 5 mg/kg/d results in lower concentrations in infants compared with children older than 2 years of age.
36
Itraconazole remains a key agent for the management of endemic mycoses worldwide and its broad spectrum of activity and availability (intravenous and OS route of administration) suggest that long-term use of ITC is affordable and practical. In addition, the ITC pharmacokinetic variability and its numerous potential drug interactions suggest that TDM is clinically necessary in order to achieve safe and effective systemic drug exposures. The results from the present study might be further explained through pharmacogenetic analyses, which could explain posaconazole level variability, also concerning gender, and why it is ineffective in some patients. Potential limitations to our study include its retrospective nature and a relatively small sample size; moreover, it lacks a standardized protocol for ITC dosing. Hence, further works applied to larger cohorts and which include the ITC active metabolite (hydroxyitraconazole) quantification are required to confirm the reported data. The lower limit of quantification (LLOQ) was considered the lowest standard on the calibration curve. Therefore, the LLOQ for ITC was 0.031 μg/mL. The considered LOD was 0.015 μg/mL. Intraand interday precision were calculated by determining the relative standard deviation (% RSD) at each QC concentration, as shown in 
T A B L E 2 Number and percentage of patients for each dose regimens

| METHODS
| Patients and inclusion criteria
| Statistical analysis
For descriptive statistics, continuous and non-normal variables were summarized as average, SD, IQR 25th-75th percentiles was calculated to measure the statistical dispersion of the data; categorical variables were described as frequency and percentage. All the variables were tested for normality with the Shapiro-Wilk test. The correspondence of each parameter was evaluated with a normal or non-normal distribution, through the Kolmogorov-Smirnov test.
The Independent Samples t test was used to compare the means of two independent groups, considering the level of statistical significance (P < .05). Pearson linear correlation coefficient (r) was used to investigate the strength of the association between two quantitative variables considering the level of statistical significance (P < .05).
Mann-Whitney U test was used to probe the influence of categorical variables on continuous ones, considering the level of statistical significance (P < .05). Any predictive power of the considered variables was finally evaluated through univariate and multivariate linear (for pharmacokinetic parameters) and logistic (considering prophylaxis efficacy cut-off 9-11 ) regression analyses. Factors with a P value <.2 in univariate analysis were considered in multivariate analysis (P < .05).
All the tests were performed with IBM SPSS Statistics 22.0 for Windows (Chicago, IL, USA).
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